<div>
  <ul>
    <li>
      <p>
        Massachusetts-based gene-editing startup CRISPR Therapeutics has entered an investment agreement to sell USD 280 million worth of shares in a direct registered offering made to selected investors for USD 71.50 per share. The offer is expected to close on February 27, 2024.
      </p>
    </li>
    <li>
      <p>
        The proceeds will be used to advance the company&rsquo;s ongoing clinical trials&nbsp;in the fields of oncology, cardiovascular, and diabetes and to accelerate the auto-immune and in vivo gene writing initiatives for 12 to 18 months.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-280-million-registered-direct">
      Press release
    </a>
  </p>
  <p>
    <a href="https://markets.businessinsider.com/news/stocks/crispr-therapeutics-announces-280-mln-direct-offering-of-shares-at-71-50-share-stock-drops-1033061639">
      Markets Business Insider
    </a>
  </p>
</div>


Human Gene Editing

<div>
 <p>Gene-editing startup, CRISPR Therapeutics, based in Massachusetts, has announced an investment deal involving the sale of its shares valued at USD 280 million at a unit price of USD 71.50. This direct registered offering made to chosen investors is anticipated to complete on February 27, 2024.</p>
 <p>This funding will be channeled towards accelerating the company's ongoing clinical trials in areas such as oncology, diabetes, and cardiovascular diseases. Additionally, the funds will be used to speed up the auto-immune and in vivo gene-editing tasks for a period of 12 to 18 months.</p>
 
</div>

CRISPR Therapeutics announces USD 280 million direct offering to advance clinical trials

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

<div>

<p>Vertex Pharmaceuticals and CRISPR Therapeutics have gained FDA approval for their gene-editing therapy, CASGEVY (exa-cel), aimed at treating transfusion-dependent beta-thalassemia in patients over 12 years. The approval follows a similar clearance given to CASGEVY (exa-cel) for treating <a href="https://sp-edge.com/updates/24785"> sickle-cell disease </a> back in December 2023.</p>

</div> <p><b>Analyst QuickTake: </b> Casgevy’s FDA approval becomes the world’s first gene-editing treatment to enter the US market, marking a milestone in the human gene-editing industry. The approval follows Casgevy’s market authorization in the UK in <a href="https://sp-edge.com/updates/24093"> November 2023 </a> , in the Kingdom of Bahrain in <a href="https://www.globenewswire.com/news-release/2023/12/02/2789644/0/en/CASGEVY-Gets-Bahrain-approval-for-treatment-marking-it-second-country-in-the-world.html"> December 2023 </a> , and in the Kingdom of Saudi Arabia <a href="https://www.pharmaceutical-technology.com/news/vertexs-casgevy-saudi/"> earlier this month </a> .&nbsp;&nbsp;</p>

Vertex-CRISPR beta-thalassemia drug receives FDA approval

PROMINENT_CATEGORY

<div>
 
 <p>Vertex Pharmaceuticals and CRISPR Therapeutics secured FDA approval for their CASGEVY (exa-cel) gene-editing therapy, providing treatment for sickle-cell disease in patients aged 12 and up. The initial availability targets up to 16,000 patients in the US with the one-time therapy costing USD 2.2 million. Vertex will handle the global development, commercialization, and manufacturing of CASGEVY with CRISPR’s assistance, alongside a USD 200 million payment to CRISPR.</p>
 
</div> <p><b>Analyst QuickTake: </b> Casgevy’s FDA approval becomes the world’s first gene-editing treatment to enter the US market, marking a milestone in the human gene-editing industry. The approval follows Casgevy’s market authorization in the UK in <a href="https://sp-edge.com/updates/24093"> November 2023 </a> and in the Kingdom of Bahrain <a href="https://www.globenewswire.com/news-release/2023/12/02/2789644/0/en/CASGEVY-Gets-Bahrain-approval-for-treatment-marking-it-second-country-in-the-world.html"> early this month. </a> Despite successfully passing the FDA process, Casgevy is still expected to face certain speed breakers, such as pricing—one of the major obstacles in the market—and therapy implementation, like the collection of stem cells, ex-vivo manipulation, and treatment with chemotherapy to eradicate the blood system.&nbsp;&nbsp;&nbsp;</p>

Vertex-CRISPR’s sickle-cell drug becomes world’s first FDA-approved gene-editing drug

<div>
 <ul>
  <li><p>CRISPR Therapeutics has laid off around 50 employees, about 10% of its workforce, due to challenging conditions in the biotech market. This comes after positive reception of its sickle-cell therapy and endorsement by UK regulators.</p></li>
  <li><p>The company is seeking partnership opportunities for its pipeline assets, focusing on in-vivo editing and immuno-oncology. It maintains a cash reserve of USD 1.74 billion and has reduced R&D expenses by 22% compared to last year.</p></li>
 </ul>
</div>

CRISPR Therapeutics lays off 10% of employees due to market challenges

The gene editing therapy, exagamglogene autotemcel (exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, has received authorization from the UK's Medicines and Healthcare Products Regulatory Agency for the treatment of sickle cell disease and beta-thalassemia in patients aged 12 and older. The drug will be initially available for up to 2,000 patients in the UK. The price of the treatment has not been disclosed. <p><b>Analyst QuickTake:</b> Initiated as part of a collaboration between Vertex and CRISPR in 2015, Casgevy marks the first CRISPR-based gene editing treatment to receive market authorization for two blood disorders. The drug is also nearing its market entry in the US, with the FDA’s decision expected on December 8, 2023 (exa-cel for sickle cell disease patients) and March 30, 2024 (for beta-thalassemia patients). Just <a href="https://sp-edge.com/updates/23331"> last month </a> , exa-cel received positive remarks from the FDA’s advisory team indicating a potentially positive decision from the FDA.</p>

Vertex-CRISPR’s gene editing drug Casgevy gets world-first approval in UK

<div>
 <ul>
  <li><p>Vertex Pharmaceuticals and CRISPR Therapeutics's gene editing therapy, exagamglogene autotemcel (exa-cel), for the treatment of sickle cell disease in patients aged 12 and older, has successfully passed through the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee, reportedly the last step before the FDA's final decision. The FDA is expected to make a decision on the therapy by December 8.</p></li>
  <li><p>The therapy, which aims to restore normal red blood cell function and alleviate symptoms, has proved to be safe and effective in preventing painful episodes associated with the disease. However, there are concerns about potential long-term safety issues.</p></li>
  <li><p>Exa-cel is the first therapy developed by the duo, which entered into a partnership in October 2015. If approved by the FDA, it will be the first gene editing therapy available for SCD patients.</p></li>
 </ul> 
</div>
Summary: Vertex Pharmaceuticals and CRISPR Therapeutics have developed exagamglogene autotemcel (exa-cel), a gene editing therapy for sickle cell disease. It has passed the FDA's advisory committee and a decision is expected by December 8. The therapy aims to restore normal red blood cell function and alleviate symptoms, effectively preventing painful episodes. However, concerns about its long-term safety remain. If approved, it will be the first gene editing therapy for SCD patients.

All Updates

CRISPR Therapeutics announces USD 280 million direct offering to advance clinical trials

Vertex-CRISPR beta-thalassemia drug receives FDA approval

Vertex-CRISPR’s sickle-cell drug becomes world’s first FDA-approved gene-editing drug

CRISPR Therapeutics lays off 10% of employees due to market challenges

Vertex-CRISPR’s gene editing drug Casgevy gets world-first approval in UK

Vertex-CRISPR sickle cell gene editing treatment exa-cel nears FDA approval

CRISPR Therapeutics beats EPS estimate by 54% in Q2 2023

CRISPR Therapeutics beats EPS analyst estimates in Q1 2023

CRISPR Therapeutics provides an FY2022 update and 2023 outlook